Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,895 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05841849 | Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer | not yet recruiting | Phase 4 | 1,028 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | May 3, 2023 | clinicaltrials |
| NCT05698186 | Thero2-01S22 in HER2-positive Breast Cancer | not yet recruiting | Phase 3 | 320 | Institut de cancérologie Strasbourg EuropeOTHER | 0 | Jan 26, 2023 |
| clinicaltrials |
| NCT05613504 | Study of Acupuncture in the Treatment of Hot Flashes in Patients With Hormone Receptor-positive Breast Cancer. | not yet recruiting | N/A | 90 | Nanjing University of Traditional Chinese MedicineOTHER | 1 | Nov 16, 2022 | clinicaltrials |
| NCT05519670 | A Phase 1b/2 Trial Evaluating Safety and Efficacy of CAPecitabine in Combination With Ni-rapaRIb in HER2-negative Advanced Breast canCEr(CAPRICE) | not yet recruiting | Phase 1 / Phase 2 | 72 | Institut Paoli-CalmettesOTHER | 0 | Aug 29, 2022 | clinicaltrials |
| NCT05505812 | Study on the Safety and Efficacy of Autogenous Tumor Infiltrates Lymphocytes for the Treatment of Advanced Breast Cancer | not yet recruiting | Early Phase 1 | 10 | The Affiliated Hospital of Qingdao UniversityOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT05460819 | Acupuncture for Hot Flashes in Patients With Hormone Receptor-positive Breast Cancer. | not yet recruiting | N/A | 90 | Nanjing University of Traditional Chinese MedicineOTHER | 1 | Jul 20, 2022 | clinicaltrials |
| NCT05285332 | Classified Treatment Strategy for De-novo Metastatic Breast Cancer After Systemic Adjuvant Therapy(CS) | not yet recruiting | N/A | 362 | Changhai HospitalOTHER | 0 | Jul 19, 2022 | clinicaltrials |
| NCT05452083 | Postoperative Radiation of Patients With Breast Cancer in Extreme Hypofractionation. | not yet recruiting | — | 100 | University of Erlangen-Nürnberg Medical SchoolOTHER | 0 | Jul 11, 2022 | clinicaltrials |
| NCT05431504 | The Efficacy and Safety of Dalpiciclib Plus Endocrine Therapy in HR-positive / HER2-negative Advanced Breast Cancer Patients With Visceral Crisis | not yet recruiting | Phase 2 | 53 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 24, 2022 | clinicaltrials |
| NCT05388500 | Protocol for Herceptin as Adjuvant Therapy With Reduced Exposure to Chemotherapy (PHARE-C)(PHARE-C) | not yet recruiting | Phase 3 | 800 | Institut de cancérologie Strasbourg EuropeOTHER | 0 | May 27, 2022 | clinicaltrials |
| NCT05287308 | Adjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world Study | not yet recruiting | N/A | 500 | Chinese Academy of Medical SciencesOTHER | 1 | Mar 31, 2022 | clinicaltrials |
| NCT05253170 | Hypo Versus Conventional Fractionation in Reconstructed-Breast Cancer Mastectomy Patients | not yet recruiting | Phase 3 | 622 | Seoul National University Bundang HospitalOTHER | 0 | Mar 11, 2022 | clinicaltrials |
| NCT04929548 | Exploratory Study of Neoadjuvant Treatment of HER2-positive Breast Cancer With Py in Combination With HP | not yet recruiting | Phase 4 | 20 | Wuhan UniversityOTHER | 0 | Jan 5, 2022 | clinicaltrials |
| NCT05172518 | Utidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-negative Locally Advanced or Metastatic Breast Cancer | not yet recruiting | Phase 3 | 512 | Sun Yat-sen UniversityOTHER | 1 | Dec 29, 2021 | clinicaltrials |
| NCT05131893 | Neoadjuvant Treatment of Breast Cancer | not yet recruiting | — | 300 | National Institute of Oncology, HungaryOTHER | 1 | Nov 23, 2021 | clinicaltrials |
| NCT05067530 | Cyclin dEpendent Kinase in tRiple nEGatIVe brEast canceR - a "Window of Opportunity" Study(CAREGIVER) | not yet recruiting | Phase 2 | 126 | Medical University of GdanskOTHER | 1 | Oct 5, 2021 | clinicaltrials |
| NCT04985552 | ciNPT in Autologous Abdominal Tissue Breast Reconstruction | not yet recruiting | N/A | 24 | McMaster UniversityOTHER | 0 | Aug 2, 2021 | clinicaltrials |
| NCT04973319 | Trastuzumab Combined With Pertuzumab for Adjuvant Treatment of Breast Cancer After Neoadjuvant Therapy | not yet recruiting | Phase 3 | 450 | Shengjing HospitalOTHER | 1 | Jul 22, 2021 | clinicaltrials |
| NCT04736589 | Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway | not yet recruiting | Phase 3 | 270 | Peking Union Medical CollegeOTHER | 1 | Feb 3, 2021 | clinicaltrials |
| NCT04426136 | A Prospective Cohort Study Comparing Disparity in Surgical Procedure (Wide Local Excision Only vs Any Other Surgery Procedures) Among the Elderly Breast Cancer Patients | not yet recruiting | — | 300 | Peking Union Medical College HospitalOTHER | 1 | Jun 11, 2020 | clinicaltrials |
| NCT04301739 | to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC) | not yet recruiting | Phase 3 | 522 | Shanghai Henlius BiotechINDUSTRY | 0 | Mar 12, 2020 | clinicaltrials |
| NCT04301375 | Omission of Surgery and Sentinel Lymph Node Dissection in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti- HER2-based Neoadjuvant Therapy (ELPIS Trial)(ELPIS) | not yet recruiting | Phase 2 | 27 | David Garcia CincaOTHER | 1 | Mar 10, 2020 | clinicaltrials |
| NCT04225858 | Avoiding Sentinel Lymph Node Biopsy in Breast Cancer Patients After Neoadjuvant Chemotherapy(ASICS) | not yet recruiting | N/A | 340 | The Netherlands Cancer InstituteOTHER | 0 | Jan 13, 2020 | clinicaltrials |
| NCT04158856 | Adjuvant Dual Anti-HER2 Therapy in Patients With Small, Node-negative, HER2-positive Breast Cancer(SHERO) | not yet recruiting | Phase 2 | 60 | xuexin heOTHER | 0 | Nov 12, 2019 | clinicaltrials |
| NCT03880097 | Enabling the Study of Metabolism in Breast Cancer Through Collection of Fresh-tissue Biopsies(ENSEMBLE) | not yet recruiting | — | 240 | University College, LondonOTHER | 0 | Mar 19, 2019 | clinicaltrials |
Data updated 23 days agoSource updated May 3, 2023source: clinicaltrials